50 results about "Bloodstream infection" patented technology

A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

The invention discloses a blood metagenome sequencing data analysis method and device and an application thereof. The blood metagenome sequencing data analysis method comprises a data quality controlstatistics and splitting step, a humanized sequence removal step, a plasmid sequence removal and internal reference comparison step, a pathogen genome sequence library comparison step and a pathogen parameter annotation step. The invention provides a blood flow infection detection device based on a blood metagenome sequencing data analysis method. According to the method and device provided by theinvention, the free nucleic acid sequences in blood are detected through a metagenome sequencing method, a bioinformatics analysis method is combined, more than 8,000 pathogenic microorganisms such as bacteria, viruses, fungi and parasites possibly existing in a blood flow infection patient body are detected at a time, and a detection result can be obtained within 24 hours at the soonest. The speed, the sensitivity, the accuracy and the efficiency of blood flow infection detection are greatly improved.

Methods and apparatus for preventing patient bloodstream infection by microorganisms during administration of various medications or fluids through IV lines. In particular, the invention reduces contamination of IV lines, connecters, stopcock valves, manifolds, ports, etc. by means of irradiation by violet and/or blue light. Each embodiment comprises a source of violet and/or blue light and an optical element optically coupled to that light source for shaping the radiation pattern of the light emitted by the light source. Preferably, a light-emitting diode or a laser diode that emits light in the desired wavelength can be used. The optical element, optically coupled to the light source, is embedded or installed in or attached to a component of an IV set, the emitted light being directed to a “point of entry” or any other stagnation point of an IV set.

The invention belongs to the field of examination of microorganisms, and relates to a method for quickly identifying bloodstream infection bacteria by a high-resolution fusion curve method. The method comprises the following steps of: performing smear gram staining on a blood culture positive culture flask to distinguish negative bacteria and positive bacteria; selectively amplifying different 16S fragments for the negative bacteria and the positive bacteria; and analyzing by the high-resolution fusion curve method. Common bloodstream infection pathogenic bacteria comprise staphylococcus aureus, staphylococcus epidermidis, enterococcus faecalis, enterococcus faecium, Escherichia coli, Klebsiella pneumoniae, acinetobacter baumannii, pseudomonas aeruginosa, enterobacter cloacae, Serratia marcescens, Klebsiella oxytoca, acinetobacter lwoffii, enterobacter aerogenes, stenotrophomonas maltophilia and burkholderia cepacia. By the method, the common bloodstream infection pathogenic bacteria can be measured quickly, efficiently and accurately, so that strong evidences are provided and precious time is striven for subsequent treatment.

A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface protein, Als1p, is a downstream effector of the filamentation regulatory pathway and is regulated by Efg1p. Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene product from the ALS1 gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

The invention belongs to the technical field of biology and discloses a kit and detection method for detecting bloodstream infectious pathogen nucleic acids. The kit for detecting bloodstream infectious pathogen nucleic acids in plasma comprises a primer group for amplifying the target sequence of free DNA of bloodstream infectious pathogen and a detection probe. The kit has excellent specificityon the DNA of free nucleic acids of bloodstream infectious pathogens, including klebsiella pneumoniae, aspergillus flavus and pseudomonas aeruginosa, in a plasma sample, and can realize quick, accurate and sensitive identification on bloodstream infectious pathogens, including klebsiella pneumoniae, aspergillus flavus, pseudomonas aeruginosa and the like, in the plasma sample. The kit and detection method are simple and convenient in operation and have good detection specificity, high sensitivity and wide detection range. Experiments indicate that the kit has the limit of detection for detecting the klebsiella pneumoniae, aspergillus flavus and pseudomonas aeruginosa respectively being 0.2, 0.4 and 0.3CFU/ml.

A method and apparatus for inserting a medical device such as a cannula tip within a peripheral vein of a human body wherein the medical device includes a micro- or nano-structured superhydrophilic basecoat and a liquid topcoat, together comprising a superhydrophobic coating, which inhibit occlusion and/or catheter related bloodstream infection.

The invention relates to the technical field of clinical detection, and discloses a processing method for a sample for detecting bloodstream infection pathogenic bacteria. The method comprises the steps: lysing erythrocytes of a to-be-tested sample, then adding a hemocyte lysate and an indication solvent into an obtained precipitate, mixing evenly, lysing proteins and incubating, centrifuging to obtain the indication solvent and an underlying precipitate, and thus obtaining a separated sample; and simultaneously extracting RNA and DNA from the separated sample, and finally obtaining a mixed nucleic acid solution. The erythrocytes are lysed firstly, and then lysis is performed with the hemocyte lysate, so pathogenic bacteria can be guaranteed to be not lysed to the greatest degree, and theseparation of the pathogenic bacteria in the blood sample is efficiently guaranteed; with use of the characteristic that the level of RNA in living bacteria is much higher than the copy number of genomic DNA, the genomic DNA and RNA of the pathogenic bacteria are extracted simultaneously. Compared with sample pretreatment in a conventional pathogenic bacteria detection scheme, the positive detection rate of trace pathogenic bacteria can be guaranteed.

The invention provides a primer and/or a probe composition for detecting cocci causing bloodstream infections and application of the primer and/or the probe composition. The invention specifically relates to the primer and/or the probe composition or a related reagent or a kit for detecting one or more of streptococcus pneumoniae, enterococcus faecalis, enterococcus faecium, streptococcus pyogenes, streptococcus agalactiae, neisseria meningitidis, coagulase negative staphylococcus and staphylococcus aureus. In this way, the detection cycle of the cocci is greatly shortened, the efficiency is improved, the detection flux is increased, and detection requirements are met; and in addition, a method and the related products have high specificity, sensitivity and accuracy.

The invention discloses a plasma free DNA marker for bloodstream infection pathogen diagnosis. The invention provides a plasma free DNA treatment method comprising the following step: selecting a fragment with a size of 60-140 bp from to-be-tested plasma free DNA. The method can be used as a sample pretreatment method for bloodstream infection pathogen detection through the plasma free DNA. The distribution range of free nucleic acid in plasma samples infected with Escherichia coli, Klebsiella pneumoniae, staphylococcus aureus, enterococcus faecium and Acinetobacter baumannii is studied, and the distribution of free nucleic acid fragments of the five bacteria in plasma is determined. The plasma free DNA marker has important significance of improving the sensitivity of pathogen detection inplasma metagenome detection and guiding the design of the length range of PCR amplification product fragments to improve the PCR detection sensitivity. The plasma free DNA marker provides a basis forpreparation of pathogen simulation samples in a plasma free DNA detection product development process.

The application provides a primer and/or probe composition for detecting bacillus for initiating blood flow infection and an application of the primer and/or probe composition, and particularly relates to one or more primer and/or probe compositions or relevant reagents or reagent kits for detecting mycobacterium tuberculosis, listeria monocytogenes, klebsiella pneumoniae, pseudomonas aeruginosa,baumanii, escherichia coli, haemophilus influenzae and proteus mirabilis, so that the detection period of the bacillus can be greatly shortened, the efficiency and the detection flux are improved, andthe primer and/or probe composition can meet detection requirements. In addition, the method and relevant products thereof disclosed by the application have high specificity, sensitivity and accuracy.

The invention belongs to the field of biological medicines, and particularly relates to a primer probe system and kit capable of simultaneously detecting multiple drug-resistant genes. Firstly, the invention discloses the primer system capable of simultaneously detecting multiple drug-resistant genes, and the primer system comprises a nucleotide sequence group with nucleotide sequences shown in SEQ ID NO: 1-24. The invention also discloses the kit comprising the primer system, and a method for detecting drug-resistant genes by using the primer system or the kit. The kit disclosed by the invention supports high-throughput detection, and can rapidly and accurately detect five bacterial drug-resistant genes with ultrahigh sensitivity, rapidly monitor the change of specific drug-resistant genes in a blood flow infection patient in real time according to quantitative/semi-quantitative detection results of the target drug-resistant genes, timely evaluate the condition of the patient, and provide adjuvant therapy suggestions for clinicians.

The invention provides a method and device for counting the number of people with new central vascular catheter related blood flow and a storage medium, and aims to solve the problem that in the priorart, the number of people with new central vascular catheter related blood flow infection is counted manually, and the efficiency is low. The method provided by the present disclosure comprises the following steps: acquiring hospitalization process information A, a department transfer record B, a treatment mode E, infection information H, statistical time, an authority department, a selected hospitalization department and a selected intubation doctor's advice to judge whether a patient suffers from new central vascular catheter related blood flow infection or not; judging each patient, and superposing output results to obtain the number of people with new central vascular catheter related blood flow infection. According to the statistical method provided by the invention, computers can beused for replacing manual work to count the number of people with new central vascular catheter related blood flow infection, so that the labor cost is saved, and the working efficiency is improved.

The invention discloses a primer pool, a kit and a method for detecting bloodstream infection by targeting high-throughput sequencing based on a multiple amplification method. The primer pool comprises a forward single-molecule tag primer and a reverse single-molecule tag primer, and each of the primers structurally comprises six parts, namely a forward single-molecule tag primer and a reverse single-molecule tag primer, and the forward single-molecule tag primer and the reverse single-molecule tag primer respectively comprises six parts: a tag universal amplification primer, a molecular tag UMI, a target specific primer sequence, an RNA residue, a DNA protection base and a blocking group sequentially arranged from a 5 '-3' end. The kit comprises the primer pool and further comprises a unique enzyme preparation and a reaction buffer. The kit can perform absolute quantification, has high specificity, can significantly reduce primer dimers, can increase or decrease primers at any time according to expected target requirements, has strong expansibility, can simultaneously perform target co-detection of RNA and DNA in a single tube, has comprehensive coverage, and reduces the detection cost.

This invention concerns improved single use caps or covers for vascular access devices such as needlefree connectors that are used, for example, in intravenous administration sets and extension sets. Removal of a single use cap or cover according to the invention from a vascular access device destroys the cap such that it cannot be reused. Such single use caps and covers will help ensure compliance with infection prevention protocols in healthcare settings, which will assist in reducing the incidence of healthcare-associated infections (HAIs), particularly catheter-related blood stream infections. Assemblies and kits its including such caps and covers, for example, IV administration and extension sets that include one or more needlefree connectors, as well as methods for using such caps and covers, are also described.

A medical apparatus, such as a cannula tip for a peripheral vein of a human body, wherein the medical apparatus includes a micro- or nano-structured superhydrophilic basecoat and a liquid topcoat, together comprising a superhydrophobic coating, which inhibit occlusion and/or catheter related bloodstream infection. The topcoat can further include compatible drugs and/or biomaterials to enhance compatibility and/or enhance durability of the topcoat.

The invention provides an artificial intelligence prediction method for hematogenous infection. The method comprises the following steps: inputting historical data of a patient subjected to blood culture; screening risk factors of infection based on a random forest, and constructing a prediction model through regularization logistic regression, K nearest neighbor, a support vector machine, the random forest, limit gradient lifting and a deep neural network algorithm; and through prediction probabilities of different methods, carrying out secondary learning through a limit gradient lifting algorithm to finally predict whether the patient suffers from hematogenous infection, and further calculating the occurrence probability of the hematogenous infection. The method is used for early warning and advanced medical intervention of blood flow infection possibly existing in an early stage, an existing computer technology is combined and applied to intelligent diagnosis of blood flow infection, and meanwhile, individualized layering of patients with blood-borne infection is realized.